Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 292, doi. 10.1002/pst.1740
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2016 AND VI 15 AND IP 4
Results: 13
1
2
An optimal stratified Simon two-stage design.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 333, doi. 10.1002/pst.1742
- By:
- Publication type:
- Article
3
A Bayesian hierarchical surrogate outcome model for multiple sclerosis.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 341, doi. 10.1002/pst.1749
- By:
- Publication type:
- Article
4
Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 324, doi. 10.1002/pst.1690
- By:
- Publication type:
- Article
5
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 287, doi. 10.1002/pst.1713
- Publication type:
- Article
6
Statistical issues in the analysis of adverse events in time-to-event data.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 297, doi. 10.1002/pst.1739
- By:
- Publication type:
- Article
7
Testing treatment effect in schizophrenia clinical trials with heavy patient dropout using latent class growth mixture models.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 349, doi. 10.1002/pst.1750
- By:
- Publication type:
- Article
8
Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 362, doi. 10.1002/pst.1751
- By:
- Publication type:
- Article
9
The analysis of incontinence episodes and other count data in patients with overactive bladder by Poisson and negative binomial regression.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 379, doi. 10.1002/pst.1752
- By:
- Publication type:
- Article
10
A modified varying-stage adaptive phase II/III clinical trial design.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 368, doi. 10.1002/pst.1753
- By:
- Publication type:
- Article
11
Safety data from randomized controlled trials: applying models for recurrent events.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 315, doi. 10.1002/pst.1757
- By:
- Publication type:
- Article
12
Analysing adverse events by time-to-event models: the CLEOPATRA study.
- Published in:
- Pharmaceutical Statistics, 2016, v. 15, n. 4, p. 306, doi. 10.1002/pst.1758
- By:
- Publication type:
- Article
13
Statistical methods for the analysis of adverse event data.
- Published in:
- 2016
- By:
- Publication type:
- Editorial